What is Alto Neuroscience, Inc.?
operates as a clinical-stage biopharmaceutical company in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 1.02B.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 8209,886 shares $5.6M | 0 |
| 3-6months | 0 | 0 |
| 6-9months | 0 | 0 |
| 9-12months | 0 | 0 |